#387 - AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field
Get the full intelligence
Search transcripts, export clips, track mentions, and explore all topics from “#387 - AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field” inside PodZeus.
In this sneak peek of Episode #387 of The Peter Attia Drive, host Peter Attia tackles one of the most frequently requested topics: peptides. He emphasizes that while peptides are often marketed as cutting-edge longevity and wellness solutions, the reality is a complex landscape of scientific promise, regulatory gray areas, and rampant commercialization. The episode aims to equip listeners with a rigorous framework for evaluating any peptide—focusing on mechanism of action, human evidence, safety, dosing, and the availability of approved alternatives—rather than promoting or dismissing peptides as a category. Attia distinguishes between FDA-approved peptide therapeutics like insulin and GLP-1 drugs and the unregulated 'biohacking' peptides sold through research-use-only channels, which dominate the wellness market. He walks through a four-tiered evaluation system to categorize peptides based on evidence quality and regulatory status, using popular examples like SS-31, Melanotin-2, CJC-1295, and BPC-157 to illustrate the framework in action. The episode also touches on manufacturing, sourcing, and the future of peptide therapeutics, while underscoring the importance of critical thinking in a space rife with hype and misinformation.
Evaluate any peptide using a four-part framework: mechanism of action, human evidence, safety/dosing, and availability of approved alternatives.
Most 'biohacking' peptides are not FDA-approved and are sold as 'research use only,' meaning their purity, safety, and efficacy are unverified.
A viable mechanism of action is essential—only ~3% of approved drugs lack a known mechanism, so absence of one should raise red flags.
Be wary of peptides with shifting claims or no human data; these often fall into the 'no compelling case' category.
Always consider whether an FDA-approved alternative with a similar risk-benefit profile exists before using a gray-market peptide.
Introduction to the AMA and the Peptide Landscape
“We're not going to talk about insulin today. We will talk a little bit about GLP-1, but from a sort of regulatory standpoint.”
Defining Peptides and Their Scientific Basis
Attia defines peptides as short chains of amino acids, emphasizing that they are naturally occurring and include well-known molecules like insulin and GLP-1. He clarifies that while peptides are not new or magical, the term in wellness culture typically refers to unapproved, injectable compounds marketed for longevity, recovery, and performance.
The Framework for Evaluating Peptides
“If there's no mechanism of action, you should be very skeptical of a drug or supplement.”
The Gray Market and Regulatory Reality of Peptides
The episode explores how most popular peptides are sold as 'research use only' despite being used by humans. Attia discusses the lack of regulation, the role of third-party testing, and the risks of sourcing from unverified suppliers. He emphasizes that 'research use only' does not mean safe or effective for humans.
Preview of Key Peptide Examples and Future Discussion
“We're going to talk through a handful of examples in a lot of detail to sort of A, cover those peptides because these are very popular ones.”
“If there's no mechanism of action, you should be very skeptical of a drug or supplement.”
“Only 3% of approved drugs have no known mechanism of action.”
“Always consider whether an FDA-approved alternative exists.”
Host
Peter Attia
person
The Peter Attia Drive
media
FDA
organization
peteratiamd.com
product
Insulin
product
GLP-1
product
Research Use Only
other
SS-31
other
BPC-157
other
CJC-1295
other
#386 - Aging clocks—what they measure, how they work, and their clinical and real-world relevance
The Peter Attia Drive • 55m • 4/6/2026
#388 — Prostate cancer screening: why current PSA guidelines are failing men and how modern tools improve early detection and save lives
The Peter Attia Drive • 46m • 4/20/2026
#389 - Thinking scientifically: why it's hard, why it matters, and a practical toolkit
The Peter Attia Drive • 53m • 4/27/2026
#392 - Genetic testing: when it's valuable, how to choose the right test, and what to do with the results
The Peter Attia Drive • 1h 2m • 5/18/2026
Get the full intelligence
Search transcripts, export clips, track mentions, and explore all topics from “#387 - AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field” inside PodZeus.
Start discovering podcast insights today
Start with a 7-day trial and explore a growing catalog of popular podcasts. No credit card required.
No credit card required • 7-day trial • Cancel anytime